Alto Neuroscience, Inc. (NYSE: ANRO), a clinical‑stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, has announced the pricing of an underwritten registered direct offering of 3,776,436 shares of its common stock at a price of US$26.48 per share. All of the shares are being offered by Alto. The gross proceeds from the offering are expected to be approximately US$100 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on July 14, 2026, subject to customary closing conditions.
Latham & Watkins LLP is advising the underwriters in the offering with a Capital Markets team led by New York partner Nathan Ajiashvili and Orange County/Bay Area partner Ross McAloon, with associates Jie Lin Nai and Justin Deuell.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
